September 21, 2021
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, KNOW AML spoke to Jacqueline Cloos, Amsterdam UMC, Amsterdam, NL. We asked, What is measurable residual disease (MRD) and why is it important in acute myeloid leukemia (AML)? Cloos begins by highlighting that the occurrence of relapse can lead to poor prognosis in acute myeloid leukemia and explains how MRD is one of the tools used to assess a patients risk of relapsing. MRD can be used to tailor treatment choices or monitor the disease during therapy, among other uses. Finally, Cloos outlines the standards around clinical implementation such as the European LeukemiaNet (ELN) MRD Working Party.